294 related articles for article (PubMed ID: 27230924)
1. Quantitative Assessment of Breast Parenchymal Uptake on 18F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI.
Leithner D; Baltzer PA; Magometschnigg HF; Wengert GJ; Karanikas G; Helbich TH; Weber M; Wadsak W; Pinker K
J Nucl Med; 2016 Oct; 57(10):1518-1522. PubMed ID: 27230924
[TBL] [Abstract][Full Text] [Related]
2. Preliminary analysis: Background parenchymal 18F-FDG uptake in breast cancer patients appears to correlate with background parenchymal enhancement and to vary by distance from the index cancer.
Kim E; Mema E; Axelrod D; Sigmund E; Kim SG; Babb J; Melsaether AN
Eur J Radiol; 2019 Jan; 110():163-168. PubMed ID: 30599855
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric
Leithner D; Helbich TH; Bernard-Davila B; Marino MA; Avendano D; Martinez DF; Jochelson MS; Kapetas P; Baltzer PAT; Haug A; Hacker M; Tanyildizi Y; Morris EA; Pinker K
J Nucl Med; 2020 Jan; 61(1):20-25. PubMed ID: 31253745
[TBL] [Abstract][Full Text] [Related]
4. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.
Mema E; Mango VL; Guo X; Karcich J; Yeh R; Wynn RT; Zhao B; Ha RS
J Magn Reson Imaging; 2018 Mar; 47(3):753-759. PubMed ID: 28646614
[TBL] [Abstract][Full Text] [Related]
5. A multiparametric [
Leithner D; Horvat JV; Bernard-Davila B; Helbich TH; Ochoa-Albiztegui RE; Martinez DF; Zhang M; Thakur SB; Wengert GJ; Staudenherz A; Jochelson MS; Morris EA; Baltzer PAT; Clauser P; Kapetas P; Pinker K
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1878-1888. PubMed ID: 31197455
[TBL] [Abstract][Full Text] [Related]
6. Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI.
Sung JS; Corben AD; Brooks JD; Edelweiss M; Keating DM; Lin C; Morris EA; Patel P; Robson M; Woods M; Bernstein JL; Pike MC
Breast Cancer Res Treat; 2018 Nov; 172(2):487-496. PubMed ID: 30140962
[TBL] [Abstract][Full Text] [Related]
7. Metabolic changes in breast cancer on dual-time-point
Kim HO; Kim BS; Kang SY; Bang JI; An J; Kim JH; Yoon HJ
Ann Nucl Med; 2020 Dec; 34(12):942-951. PubMed ID: 32974848
[TBL] [Abstract][Full Text] [Related]
8. MRI Background Parenchymal Enhancement Is Not Associated with Breast Cancer.
Bennani-Baiti B; Dietzel M; Baltzer PA
PLoS One; 2016; 11(7):e0158573. PubMed ID: 27379395
[TBL] [Abstract][Full Text] [Related]
9. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
[TBL] [Abstract][Full Text] [Related]
10. Background parenchymal enhancement and fibroglandular tissue on breast MRI in women with high genetic risk: Are changes before and after risk-reducing salpingo-oophorectomy associated with breast cancer risk?
Bermot C; Saint-Martin C; Malhaire C; Sebbag-Sfez D; Mouret-Fourme E; Carton M; Thibault FE
Eur J Radiol; 2018 Dec; 109():171-177. PubMed ID: 30527300
[TBL] [Abstract][Full Text] [Related]
11. The impact of bilateral salpingo-oophorectomy on breast MRI background parenchymal enhancement and fibroglandular tissue.
Price ER; Brooks JD; Watson EJ; Brennan SB; Comen EA; Morris EA
Eur Radiol; 2014 Jan; 24(1):162-8. PubMed ID: 23982290
[TBL] [Abstract][Full Text] [Related]
12. Inter- and intra-observer agreement of BI-RADS-based subjective visual estimation of amount of fibroglandular breast tissue with magnetic resonance imaging: comparison to automated quantitative assessment.
Wengert GJ; Helbich TH; Woitek R; Kapetas P; Clauser P; Baltzer PA; Vogl WD; Weber M; Meyer-Baese A; Pinker K
Eur Radiol; 2016 Nov; 26(11):3917-3922. PubMed ID: 27108300
[TBL] [Abstract][Full Text] [Related]
13. Impact of tamoxifen on amount of fibroglandular tissue, background parenchymal enhancement, and cysts on breast magnetic resonance imaging.
King V; Kaplan J; Pike MC; Liberman L; David Dershaw D; Lee CH; Brooks JD; Morris EA
Breast J; 2012; 18(6):527-34. PubMed ID: 23002953
[TBL] [Abstract][Full Text] [Related]
14. Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.
King V; Goldfarb SB; Brooks JD; Sung JS; Nulsen BF; Jozefara JE; Pike MC; Dickler MN; Morris EA
Radiology; 2012 Sep; 264(3):670-8. PubMed ID: 22771878
[TBL] [Abstract][Full Text] [Related]
15. Fully automatic quantification of fibroglandular tissue and background parenchymal enhancement with accurate implementation for axial and sagittal breast MRI protocols.
Wei D; Jahani N; Cohen E; Weinstein S; Hsieh MK; Pantalone L; Kontos D
Med Phys; 2021 Jan; 48(1):238-252. PubMed ID: 33150617
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers.
Wu S; Weinstein SP; DeLeo MJ; Conant EF; Chen J; Domchek SM; Kontos D
Breast Cancer Res; 2015 May; 17():67. PubMed ID: 25986460
[TBL] [Abstract][Full Text] [Related]
17. Mammographic density, MRI background parenchymal enhancement and breast cancer risk.
Pike MC; Pearce CL
Ann Oncol; 2013 Nov; 24 Suppl 8(Suppl 8):viii37-viii41. PubMed ID: 24131968
[TBL] [Abstract][Full Text] [Related]
18. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI.
Koo HR; Moon WK; Chun IK; Eo JS; Jeyanth JX; Chang JM; Cho N; Kang KW
Eur J Radiol; 2013 Oct; 82(10):1738-42. PubMed ID: 23806533
[TBL] [Abstract][Full Text] [Related]
19. Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI.
King V; Gu Y; Kaplan JB; Brooks JD; Pike MC; Morris EA
Eur Radiol; 2012 Dec; 22(12):2641-7. PubMed ID: 22752463
[TBL] [Abstract][Full Text] [Related]
20. Could parenchymal enhancement on contrast-enhanced spectral mammography (CESM) represent a new breast cancer risk factor? Correlation with known radiology risk factors.
Savaridas SL; Taylor DB; Gunawardana D; Phillips M
Clin Radiol; 2017 Dec; 72(12):1085.e1-1085.e9. PubMed ID: 28870431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
